Abdera combines advanced antibody engineering with radiotherapeutics to create targeted cancer medicines. The company utilizes its ROVEr platform to develop novel radiopharmaceuticals that deliver radionuclide payloads against solid tumor targets. This approach focuses on maximizing therapeutic effect while mitigating systemic toxicities associated with cancer treatment.

Auron utilizes a proprietary database of single-cell genomic data and an AI-powered computational platform to map the developmental pathways of cancer cells compared to healthy cells. This approach aims to transform malignant cells into normal functioning cells, addressing the limitations of traditional cancer therapeutics that primarily focus on cell killing.

Boulder provides telehealth services for individuals with substance use disorders, utilizing a secure mobile app to deliver medication-assisted treatment and personalized care plans. The platform addresses the barriers of in-person visits by offering convenient access to addiction treatment and ongoing support from a dedicated care team.

Candid Therapeutics develops targeted therapies for autoimmune diseases, focusing on novel mechanisms of action. Their pipeline includes candidates designed to modulate immune pathways and improve patient outcomes. The company aims to address unmet clinical needs with scientifically validated drug candidates.

Dualitas provides a high‑throughput DualScreen™ Bispecific Discovery Engine that functionally screens over 100,000 bispecific antibody combinations across the entire cell‑surface proteome. By identifying synergistic co‑target pairs and cell‑surface proximity mechanisms, the platform generates bispecific candidates with greater potency, higher maximal efficacy, and immune modulation beyond conventional inhibitors for autoimmune, allergic, and other inflammatory diseases.

Empirico uses proprietary platforms to discover and develop siRNA therapeutics that mimic protective human genetic variants, enabling precise modulation of disease‑relevant genes.

Entact Bio is developing enhancement-targeting chimeras (ENTACs) that utilize deubiquitylases to improve the function of critical proteins, addressing issues of protein deficiency, mislocation, and suboptimal activity in various diseases. Their Encompass™ platform enables the identification and optimization of these ENTACs to target previously undruggable pathways and treat complex genetic disorders.

evermore administers a Smart Benefits platform that connects members to necessary products and services through a single card and network. The platform dynamically manages benefits like healthy food allowances and OTC access, aligning incentives across payers and retailers. This integration of health, retail, and self-reported data drives personalized engagement and measurable health outcomes.

Fuze Health provides a unified, API‑driven platform that integrates disease screening, genomics, telehealth, digital pharmacy, and patient engagement into a single digital ecosystem. The solution enables health systems, plans, employers, and life‑science companies to streamline data, improve early detection, and deliver personalized, adherent care through AI‑powered analytics and real‑time support.

Renasant Bio is developing oral small molecule therapies to address the root cause of autosomal dominant polycystic kidney disease (ADPKD). Their approach focuses on restoring the function of polycystin proteins, aiming to halt disease progression and potentially reverse cyst growth.

Rhino provides a federated computing platform that lets multiple organizations run AI and analytics workloads on their own edge environments, keeping raw data on‑premise. The system securely aggregates results and enforces policy‑driven governance, enabling collaborative insights without exposing sensitive data.

Satellos Bioscience is developing small molecule therapeutics that target dystrophin-independent pathways to promote muscle regeneration in patients with Duchenne muscular dystrophy. Their approach aims to enhance muscle tissue growth and repair, addressing the critical need for effective treatments for this debilitating condition.

Umoja Biopharma develops an in vivo CAR T-cell gene therapy platform that reprograms the immune system to target solid tumors and hematological cancers resistant to current treatments. This approach aims to achieve durable remissions in patients by enhancing the body's natural ability to fight cancer.